Clinical trials: sponsored by OHSU Knight Cancer Institute
Ovarian Cancer, Peritoneal Cancer
Abraxane/Bevacizumab
The protocol will study the effect of the combination of two drugs-Abraxane and Bevacizumab-on a subject's ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- Trial name
- NCT01821859
- Testing
- Abraxane, Bevacizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- OHSU Knight Cancer Institute
Philadelphia Chromosome Positive (Ph+) Leukemias, Chronic Myeloid Leukemia
Compassionate Use Ponatinib
The main purpose of this protocol is to provide expanded access to the study drug (Ponatinib/AP24534) for people with imatinib-, dasatinib-, and nilotinib- resistant/intolerant Philadelphia Chromosome Positive (Ph+) Leukemias.
- Trial name
- NCT01549548
- Testing
- Ponatinib
- Where
- United States
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer
Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer
RATIONALE: Androgens can cause the growth of breast cancer cells. Hormone therapy using dehydroepiandrosterone (DHEA) may fight breast cancer by blocking the use of androgen by the tumor cells.
- Trial name
- NCT00516542
- Testing
- letrozole, DHEA, pharmacological study
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- OHSU Knight Cancer Institute
Leukemia, Myelodysplastic Syndromes
Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy, such as treosulfan and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00253513
- Testing
- fludarabine, treosulfan, allogeneic blood or bone marrow transplantation
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
Flu/TBI in Treating Patients Not Responding to Previous Hormone Therapy
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00242931
- Testing
- Nonmyeloablative stem cell conditioning regimen
- Sponsor
- OHSU Knight Cancer Institute
Kidney Cancer
Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00243009
- Testing
- cyclosporine, fludarabine phosphate, mycophenolate mofetil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- OHSU Knight Cancer Institute
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00253552
- Testing
- filgrastim, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- OHSU Knight Cancer Institute
Multiple Myeloma and Plasma Cell Neoplasm
Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, dexamethasone, and ascorbic acid, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00227682
- Testing
- ascorbic acid, arsenic trioxide, dexamethasone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Leukemia
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell…
- Trial name
- NCT00053248
- Testing
- arsenic trioxide, imatinib mesylate
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer, Menopausal Symptoms
Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer
RATIONALE: Raloxifene and exercise may improve bone health and quality of life in breast cancer survivors. Assessing bone health and quality of life may improve the ability to plan treatment.
- Conditions
- Breast Cancer, Menopausal Symptoms, Osteoporosis
- Trial name
- NCT00031811
- Testing
- raloxifene, quality-of-life assessment
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as leuprolide and bicalutamide, may stop the adrenal glands from making androgens.
- Trial name
- NCT00244920
- Testing
- bicalutamide, leuprolide acetate, squalamine lactate
- Sponsor
- OHSU Knight Cancer Institute
Colonoscopy
Comparing Warm Versus Cool Temperature Water During Colonoscopy
The purpose of this study will be to determine if the temperature of water used during insertion of colonoscopy makes a difference in patient discomfort and sedation requirements.
- Trial name
- NCT01322724
- Testing
- Warm vs Cool water
- Where
- United States
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute
Chronic Myeloproliferative Disorders
Imatinib Mesylate in Treating Patients With Myelofibrosis
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of imatinib mesylate and how well it works in…
- Trial name
- NCT00245128
- Testing
- imatinib mesylate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- OHSU Knight Cancer Institute
Leukemia
Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
RATIONALE: Vaccines made from a peptide may help the body build an effective immune response to kill cancer cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with chronic phase…
- Trial name
- NCT00428077
- Testing
- bcr-abl peptide vaccine, reverse transcriptase-polymerase chain reaction
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- OHSU Knight Cancer Institute